Tag: T2D

Generic Dapagliflozin Is Here. For 40 Million Americans With Type 2 Diabetes, That’s a Big Deal.

📌 The essentials The FDA has approved the first generic versions of dapagliflozin (Farxiga) tablets, the first SGLT2 inhibitor to reach generic status in the United States. Multiple generic manufacturers received approval simultaneously. Available doses: 5 mg and 10 mg tablets. Generic approval covers: type 2 diabetes (glycemic control and cardiovascular risk reduction) and reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and cardiovascular disease or multiple cardiovascular risk factors. The brand-name Farxiga retains additional approved indications (heart failure with preserved ejection fraction, chronic kidney disease) that the generics do not yet carry. Current approximate pricing: brand-name Farxiga runs $550 to $650 per month without insurance; generic dapagliflozin is running approximately $290 to $410 per month with discount coupons (GoodRx, SingleCare) as of April 2026. Confirm current pricing at GoodRx.com/dapagliflozin as prices will continue to change with market competition. Verify therapeutic equivalence: check the FDA Orange Book to confirm which manufacturers have received “AB” ratings, indicating interchangeability.

If you have been prescribing or taking Farxiga (dapagliflozin) for any length of time, you already know the conversation that tends to come up at refill time: the price. Without insurance, a 30-day supply of brand-name Farxiga runs between $550 and $650 per month. For a medication that many patients need to take daily and indefinitely, that is a meaningful barrier. The FDA’s approval of the first generic versions of dapagliflozin tablets changes that equation.

Multiple generic manufacturers have received approval simultaneously, and while generic pricing is not always as low as patients hope immediately after launch, the competitive pressure that comes with multiple manufacturers is what ultimately drives costs down. This is how the generic drug system is supposed to work.

Dapagliflozin: More Than a Diabetes Drug

Dapagliflozin belongs to a class of medications called SGLT2 inhibitors, short for sodium-glucose cotransporter 2 inhibitors. The mechanism is straightforward: the kidneys normally filter glucose from the blood and then reabsorb almost all of it back into circulation. SGLT2 inhibitors block the transporter protein responsible for that reabsorption, so excess glucose gets excreted in the urine instead. Lower blood glucose, less cardiovascular strain, less kidney filtration burden.

What made dapagliflozin and its SGLT2 classmates remarkable, and what eventually transformed both cardiology and nephrology practice, was what came out of the cardiovascular outcomes trials that the FDA mandated for all new diabetes drugs after 2008. Researchers expected to show the drugs were not harmful. What they found instead was that they were actively protective: significantly reducing hospitalizations for heart failure and slowing kidney disease progression, even in patients without diabetes.

The DAPA-HF trial, published in the New England Journal of Medicine in 2019, showed dapagliflozin reduced a composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with heart failure with reduced ejection fraction, including patients who did not have type 2 diabetes. The DAPA-CKD trial showed it reduced risk of a sustained decline in kidney function, end-stage kidney disease, or death from kidney or cardiovascular causes by 39% in patients with chronic kidney disease, again including non-diabetic patients. These were not minor findings. They were class-redefining.

The indications that dapagliflozin currently carries, and what the generic covers Dapagliflozin’s full FDA-approved indication list includes: type 2 diabetes in adults (glycemic control plus cardiovascular risk reduction); reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors; heart failure with reduced ejection fraction (regardless of diabetes status); heart failure with preserved ejection fraction; and chronic kidney disease in adults at risk of progression. The generic approval currently covers the type 2 diabetes and heart failure hospitalization risk reduction indications specifically. The additional heart failure and CKD indications remain on the brand label but are not yet part of the generic labeling. As the evidence base matures, generic labeling may expand to match. For the complete current list, the FDA prescribing information is the authoritative source.

Why Generic Approval Matters More for This Drug Than Most

Type 2 diabetes affects more than 40 million Americans, with 90 to 95% of all diabetes cases falling into this category. It is a condition that disproportionately affects lower-income populations and communities of color, exactly the populations for whom a $600-per-month medication is least accessible.

Despite its strong evidence base, adoption of SGLT2 inhibitor therapy in clinical practice has remained well below what guidelines recommend, and cost is consistently cited as a primary barrier. A 2025 review in npj Metabolic Health and Disease noted this explicitly, pointing to cost and clinician familiarity as the two main obstacles to uptake of a drug class with clear guideline support for reducing cardiovascular and kidney disease burden.

Generic availability does not immediately solve the cost problem, but it starts the clock. With discount coupons through services like GoodRx or SingleCare, generic dapagliflozin is currently available in the range of $290 to $410 per month for a 30-day supply, compared to $550 to $650 for the brand. That is a meaningful improvement, though still not cheap. As more manufacturers enter the market over the coming months, prices should continue to fall.

Current approximate price landscape (30-day supply):

Option	Without Insurance	With Discount Coupon
Brand-name Farxiga	$550 to $650/month	~$288 (GoodRx)
Generic dapagliflozin	$400 to $500/month	$290 to $410 (GoodRx/SingleCare)
With commercial insurance	Varies by plan	Copay $0 to $75 typical
AZ&Me patient assistance	Potentially $0	Eligibility required

AZ&Me is AstraZeneca’s patient assistance program for brand-name Farxiga. Patients who meet income eligibility can receive free medication. Details at azandme.com. Generic dapagliflozin is not covered under this program. Pricing figures are approximate as of April 2026 and subject to change.

What “Therapeutic Equivalence” Actually Means

A common question when a generic is approved: is it really the same? The short answer is yes, with a specific technical meaning. The FDA requires generics to demonstrate bioequivalence: they must deliver the same active ingredient in the same form, at the same dose, producing the same blood levels over the same time frame as the brand. The inactive ingredients (fillers, binders, coatings) can differ, which occasionally matters for patients with specific allergies or sensitivities, but the therapeutic effect is required to be equivalent.

Generics approved under this standard receive an “AB” rating in the FDA’s Orange Book, the Approved Drug Products database, indicating they are interchangeable at the pharmacy level without requiring a new prescription. You can check the Orange Book at accessdata.fda.gov/scripts/cder/ob/ to confirm which manufacturers have received approval and their equivalence rating.

Safety: The Generic Carries the Same Label

Generic dapagliflozin carries the same prescribing information, contraindications, warnings, and precautions as brand-name Farxiga. These are worth knowing, particularly for patients or prescribers newer to this drug class.

Contraindications

Known serious hypersensitivity to dapagliflozin or any excipient in the formulation
eGFR below the threshold specified in the label for the relevant indication (review the current label for the specific eGFR cutoffs by indication)

Key warnings to discuss with patients

Diabetic ketoacidosis (DKA): Can occur even with near-normal blood glucose (euglycemic DKA), a well-documented and sometimes underrecognized risk. Patients should be counseled to hold dapagliflozin before surgery and to recognize DKA symptoms including nausea, vomiting, abdominal pain, fatigue, and difficulty breathing.

Volume depletion: The osmotic diuretic effect can cause dehydration and hypotension, particularly relevant in older patients or those on diuretics. Assess volume status before initiating in high-risk patients.

Urinary tract and genital infections: The glucosuria that makes SGLT2 inhibitors effective also creates a more hospitable environment for yeast and bacterial infections. Genital mycotic infections are common, particularly in women. Counsel patients to report symptoms and maintain good hygiene.

Fournier’s gangrene: A rare but serious necrotizing fasciitis of the genitalia has been reported across the SGLT2 class. Patients with symptoms including pain, tenderness, redness, or swelling in the genital or perineal area should seek immediate care.

Lower limb amputations: A risk signal first identified with canagliflozin. The signal for dapagliflozin is less clearly established but warrants monitoring in high-risk patients including those with peripheral arterial disease or diabetic neuropathy.

As the SGLT2 class StatPearls reference notes, despite the substantial clinical advantages of this drug class, therapy requires attention to safety considerations including volume depletion, genital infections, diabetic ketoacidosis, and potential lower extremity complications. These are established safety signals, not new or unexpected findings with the generic.

A note on perioperative management SGLT2 inhibitors should generally be held before scheduled surgery due to the risk of euglycemic DKA. The recommended hold period varies by guideline. The ADA recommends holding for at least 3 to 4 days prior to major surgery. This is a counseling point worth building into any practice that prescribes dapagliflozin, especially now that more patients may receive it via generic without a specialist involved in initiation.

The Bigger Picture: Where This Drug Class Is Heading

Generic dapagliflozin’s arrival coincides with a remarkable moment for this drug class. SGLT2 inhibitors, initially developed as diabetes drugs, have become foundational therapies in cardiology and nephrology, a transformation that has happened faster than almost any comparable pharmacological shift in recent memory.

The 2024 to 2025 research cycle extended the evidence base further, with large meta-analyses showing benefits in acute myocardial infarction, acute decompensated heart failure, and non-diabetic chronic kidney disease without albuminuria. Trials are now exploring effects on cognitive decline, atrial fibrillation, and liver disease. Next-generation SGLT2-based compounds and dual SGLT1/SGLT2 inhibitors are in Phase II development.

There is also the Medicare context. Dapagliflozin and empagliflozin were selected as two of the first drugs for price negotiation under the Inflation Reduction Act, with negotiated prices taking effect in 2026. Generic competition and Medicare negotiation happening simultaneously represent an unusual convergence of affordability pressure on a single drug class. If that convergence translates to real-world access, it could meaningfully reduce the burden of undertreated cardiovascular and kidney disease in the populations that carry the highest risk.

For related coverage on how access to GLP-1 medications is being broadened through higher-dose approvals, see our post on Wegovy HD and the STEP UP trial data. For a parallel access story in diabetes care, our post on GLP-1 medications and PCOS covers how prescribing patterns in metabolic disease are shifting rapidly beyond original approved indications.

What to Watch Going Forward

Supply and availability

As of early 2026, generic manufacturers are still ramping up to full production capacity, which means spotty availability at some pharmacies, particularly in smaller markets. Calling ahead before a patient makes a trip to the pharmacy is practical advice worth passing along. Drug availability search tools like Medfinder can also help patients locate stock in real time.

Insurance formulary adjustments

Generic approval often triggers formulary changes. Some insurance plans may shift from covering brand-name Farxiga to preferring the generic, or may adjust tier placement. Patients on Farxiga who are told their insurance no longer covers it or covers it differently should check their updated formulary rather than assume the drug is not covered at all. Generic dapagliflozin should be therapeutically equivalent and typically at lower cost.

Expanding indications for the generic

The current generic approval covers type 2 diabetes and heart failure hospitalization risk reduction. As the evidence base continues to mature for heart failure with preserved ejection fraction and chronic kidney disease, it is worth watching whether FDA labeling for generic dapagliflozin expands to match the brand’s full approved indications.

Sources

FDA announcement: FDA Approves First Generic Dapagliflozin Tablets. FDA.gov.

Farxiga original FDA approval (T2D/CV): FDA approves dapagliflozin to reduce risk of hospitalization for heart failure in adults. FDA.gov.

Farxiga full prescribing information: Dapagliflozin prescribing information. accessdata.fda.gov.

Orange Book: FDA Approved Drug Products with Therapeutic Equivalence Evaluations. accessdata.fda.gov.

FDA generic drug bioequivalence: Generic Drug Facts. FDA.gov.

DAPA-HF trial: McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008.

DAPA-CKD trial: Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446.

SGLT2 inhibitor class reference: Padda IS et al. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. StatPearls. Updated September 2025.

Next-generation SGLT2 compounds: Cohen TD et al. Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives. Biomedicines. 2026;14(1):81.

Access barriers review: SGLT2 inhibitors across various patient populations in the era of precision medicine. npj Metabolic Health and Disease. 2025.

Inflation Reduction Act Medicare negotiation: Medicare Drug Price Negotiation. CMS.gov.

FDA cardiovascular outcomes trial guidance: Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies. FDA.gov.

Fournier’s gangrene safety communication: FDA Drug Safety Communication: Rare but serious infection of the genitals and area around them. FDA.gov.

ADA perioperative guidance: Diabetes Care in the Hospital. ADA Standards of Care 2023.

Pricing tools: GoodRx: dapagliflozin | SingleCare: dapagliflozin

Patient assistance: AstraZeneca AZ&Me Program. azandme.com.

CDC type 2 diabetes: Type 2 Diabetes. CDC.gov.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Drug pricing information reflects approximate figures at time of publication and is subject to change. Always consult a qualified healthcare provider or pharmacist regarding medication decisions, including decisions about switching from a brand-name product to its generic equivalent.

April 9, 2026

GLP-1 Drugs and Suicidal Thoughts: The FDA Reviewed 107,910 Patients and 2.2 Million Real-World Users. What It’s Now Asking Drug Makers to Remove.

📌 Where This Review Stands as of January 2026: Read This First January 13, 2026: The FDA issued an updated Drug Safety Communication concluding that its comprehensive review, spanning 91 clinical trials, 107,910 patients, and a real-world cohort of 2.24 million users, found no evidence of increased suicidal behavior or ideation with GLP-1 receptor agonists. The FDA has formally requested removal of suicidality warnings from the prescribing information for semaglutide, tirzepatide, and liraglutide. This is the FDA’s clearest signal that it considers the concern resolved. The European Medicines Agency reached a similar conclusion in April 2024 after its own independent review. Important nuance: the FDA’s update also examined anxiety, depression, irritability, and psychosis, and found no increased risk for these psychiatric adverse events either. Patients should not stop GLP-1 medications without consulting their healthcare provider. If you are experiencing mood changes or distressing thoughts, contact your clinician and call or text 988.

When a drug is used by tens of millions of people, any signal in the adverse event database draws attention, even when that signal does not establish causation. That is the story of how GLP-1 receptor agonists and suicidality became a major pharmacovigilance question, why it took more than two years and two regulatory agencies to work through the evidence, and why the answer that emerged from one of the largest drug safety analyses ever conducted matters for patients and clinicians navigating this question.

The conclusion: the FDA reviewed the evidence systematically and comprehensively. It found no causal link. It is now asking manufacturers to remove the suicidality warning language. Getting to that conclusion required understanding why the signal appeared, why it was worth investigating seriously, and why the initial reports did not mean what some feared.

How the Signal Emerged and Why It Was Worth Investigating

GLP-1 receptor agonists, the class that includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and others, have become among the most widely prescribed drugs in modern medicine. More than 40 million Americans have taken semaglutide alone. At that scale, rare adverse events generate measurable counts in pharmacovigilance databases even when those events occur at the same rate as in untreated patients.

The concern originated in Europe. In 2023, the European Medicines Agency received reports of suicidal thoughts and self-injury in patients taking semaglutide and liraglutide. The EMA initiated a formal safety review. The FDA, which had already added precautionary language to certain GLP-1 labels, also began a systematic evaluation. In January 2024, the FDA announced preliminary findings with no evidence of a causal link, but stated the review was not yet complete. The January 13, 2026 Drug Safety Communication represents the completed review.

Why the initial signal was plausible enough to investigate seriously Several biological mechanisms made a GLP-1/suicidality connection worth examining. GLP-1 receptors are expressed not just in the pancreas and gut but throughout the brain, including in regions involved in mood regulation, reward processing, and appetite. Semaglutide is known to reduce what is sometimes described as “food noise,” the intrusive, preoccupying thoughts about food. Whether this appetite-suppressing CNS effect could, in some patients, contribute to a broader hedonic blunting or mood change was a reasonable hypothesis to test. Additionally, rapid weight loss from any cause is associated with increased risk of mood disruption, nutritional deficiency, and in some cases a paradoxical worsening of psychological wellbeing when results do not match expectations. Patients who begin GLP-1 therapy with unrealistic expectations and experience slower-than-expected weight loss may be particularly vulnerable. An umbrella review published in Healthcare (MDPI) in 2025 specifically identified unrealistic treatment expectations as a factor associated with suicidal ideation in GLP-1 users, independently of any pharmacological mechanism. The precedent from lorcaserin (Belviq), a weight-loss drug withdrawn in 2020 due to cancer risk that had also carried a suicidality warning, created additional regulatory pressure to examine this class carefully. And context matters: obesity and type 2 diabetes both independently elevate the baseline risk of depression and suicidality, meaning any population study in GLP-1 users is working against a backdrop of elevated baseline risk.

What the FDA’s Review Actually Examined

The January 2026 Drug Safety Communication represents one of the most comprehensive pharmacovigilance analyses ever conducted for a drug class. The FDA’s review incorporated three distinct streams of evidence.

1. FAERS adverse event report review

The FDA conducted detailed reviews of suicidal thoughts and action reports in its Adverse Event Reporting System (FAERS) database. It found that the reports were limited in detail and that suicidal events could be explained by other factors, including the underlying conditions for which GLP-1s are prescribed. A peer-reviewed FAERS analysis by McIntyre et al. (2024), applying Bradford Hill criteria for causality assessment, found disproportionate reporting of suicidal ideation with semaglutide and liraglutide, but no disproportionate reporting of actual suicidal behavior, suicide attempts, or completed suicide for any GLP-1. Their conclusion: no causal link exists when confounders are considered.

2. Meta-analysis of 91 clinical trials (107,910 patients)

The FDA conducted a meta-analysis pooling data from 91 placebo-controlled clinical trials of GLP-1 medications: 60,338 patients treated with GLP-1s and 47,572 treated with placebo. This is among the largest drug safety meta-analyses ever assembled for a single question. The results did not demonstrate an increased risk of suicidal behavior or ideation with GLP-1s. The analysis also examined related psychiatric outcomes, including anxiety, depression, irritability, and psychosis, and found no increased risk for any of these either.

3. Sentinel System real-world cohort study (2.24 million users)

The FDA’s Sentinel System, a large database of health insurance claims and patient health records, was used to conduct a retrospective cohort study comparing the risk of intentional self-harm between new users of GLP-1 receptor agonists and new users of SGLT2 inhibitors. The study included 1,161,983 GLP-1 users and 1,081,155 SGLT2 users. This real-world analysis found no increased risk of intentional self-harm with GLP-1 use.

Evidence stream	Scale	Finding
FAERS adverse event review	Detailed case-by-case review	No clear causal relationship; limited report detail; events explainable by underlying conditions
Clinical trial meta-analysis	91 trials, 107,910 patients (60,338 GLP-1 vs 47,572 placebo)	No increased risk of suicidal ideation, behavior, anxiety, depression, irritability, or psychosis
Sentinel real-world cohort	2,243,138 users (1.16M GLP-1 vs 1.08M SGLT2 inhibitor)	No increased risk of intentional self-harm with GLP-1 use
EMA independent review (April 2024)	EU-based pharmacovigilance and clinical trial data	Evidence insufficient to support causal association; no label change warranted

Beyond the FDA: What Independent Research Shows

The regulatory conclusions are consistent with the direction of the independent peer-reviewed literature, which has grown substantially since 2023.

The Nature Medicine study (semaglutide vs. comparators, n=240,618)

A study published in Nature Medicine, led by researchers at Case Western Reserve University and the National Institute on Drug Abuse, used electronic health records from 240,618 patients with overweight or obesity prescribed semaglutide or a non-GLP-1 medication for weight management. Semaglutide was associated with a lower risk of incident suicidal ideation (HR 0.27) and recurrent suicidal ideation (HR 0.44) compared with other agents. Dr. Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA), was explicit about the appropriate interpretation of this finding in the publication’s commentary: the study does not indicate that taking semaglutide could reduce the risk of suicidal ideation or that it actively protects against suicidal ideation, as such a conclusion would require clinical trials.

Mendelian randomization: no genetic link

A Mendelian randomization study by Nguyen (2024) used genetic variants associated with GLP-1 pathway activity as proxies for long-term drug-like exposure. This approach can detect causal biological effects independent of confounders. The study found no causal evidence linking the glycemic and BMI-lowering effects of GLP-1 receptor agonists to an increased risk of suicide attempts, either in the general population or in individuals with pre-existing mental health conditions.

Systematic reviews and meta-analyses

A 2025 systematic review in Diabetes/Metabolism Research and Reviews (Bushi et al.) pooled observational cohort and case-control studies. It found no consistent association between GLP-1 use and increased suicidal ideation or behavior in the general diabetes or obesity population. An umbrella review published in Healthcare (MDPI) in 2025 synthesized 12 reviews and meta-analyses and found results consistent across studies, with no significant association between GLP-1 use and suicidality. A meta-analysis of 31 RCTs involving approximately 85,000 patients found no significant difference in psychiatric disorders (OR 0.97; 95% CI 0.83 to 1.15) or suicidal behavior (OR 0.86) between GLP-1 and placebo arms.

The Critical Confounding Issue: Obesity and Diabetes Independently Elevate Suicide Risk

This point deserves its own section because it is the single most important piece of context for interpreting any report connecting GLP-1 drugs to suicidality.

Obesity is independently associated with elevated rates of depression, anxiety, and suicidal ideation. Type 2 diabetes is independently associated with the same. People prescribed GLP-1 receptor agonists are, by definition, drawn from a population with higher baseline risk of psychiatric adverse events than the general population. When a drug is given to millions of people from a higher-risk population, adverse events including suicidal ideation will be reported, even if the drug itself plays no causal role.

This is called confounding by indication: the condition being treated (obesity, diabetes) is itself a risk factor for the outcome being studied (suicidal ideation). Properly controlled studies, using comparator groups of patients with the same underlying conditions on different medications, or using the Mendelian randomization approach to remove confounders entirely, consistently fail to find excess suicidal risk attributable to GLP-1 drugs.

The co-prescription signal: a nuance worth knowing One finding from the Bushi et al. systematic review warrants specific clinical attention: patients co-prescribed antidepressants showed a substantially higher reporting odds ratio for suicidal ideation (ROR 4.45; 95% CI 2.52 to 7.86), and those co-prescribed benzodiazepines showed a similarly elevated signal (ROR 4.07; 95% CI 1.69 to 9.82). This suggests that individuals with pre-existing mental health conditions who are also taking GLP-1 drugs may warrant closer psychiatric monitoring. This does not mean GLP-1 drugs caused the suicidality in these patients. It almost certainly reflects the fact that patients already on antidepressants or benzodiazepines have higher baseline psychiatric vulnerability. But it is a reasonable clinical signal: if a patient is already being treated for depression or anxiety and starts a GLP-1, maintaining existing mental health follow-up is sensible practice regardless of the FDA’s label change.

What the FDA Is Asking Drug Makers to Remove and What Stays

The January 2026 Drug Safety Communication is explicit: the FDA is requesting removal of suicidal behavior and ideation warnings from the prescribing information for semaglutide, tirzepatide, and liraglutide. This is a formal regulatory request to manufacturers, not a unilateral FDA label change. Manufacturers submit the proposed language and the FDA approves it. The practical effect is the same.

What stays in the label: the established, class-wide safety profile for GLP-1s including gastrointestinal effects, thyroid C-cell tumor risk for injectable GLP-1s, pancreatitis risk, and the contraindications relevant to each specific drug. None of these are affected by the suicidality review.

The FDA also emphasized that despite requesting label removal, clinicians should continue to be prepared to discuss the findings with patients and to refer individuals who report suicidal ideation or behavior to mental health professionals, not because the drug is causing it, but because the population taking these drugs has higher baseline psychiatric risk that warrants clinical awareness.

For Patients: What This Means in Practice

Do not stop your GLP-1 medication based on the suicidality concern. The evidence does not support a causal link. Stopping abruptly without medical guidance can worsen blood sugar control or cause rebound weight gain. Read our post on what happens when semaglutide is discontinued for more context on managing GLP-1 therapy transitions.

Do tell your prescribing clinician about any changes in mood, new or worsening depression, or distressing thoughts. This applies to any medication in any patient and is not specific to GLP-1s, but it is always important to keep your care team informed.

If you already have a history of depression or anxiety, ensure your mental health provider is aware you are starting a GLP-1. Not because of a drug risk, but because any significant metabolic change, body image shift, or treatment expectation mismatch can affect mental health in people already managing psychiatric conditions.

If you are having thoughts of self-harm or suicide, call or text 988 (U.S. Suicide and Crisis Lifeline) any time, or go to your nearest emergency department. Do not wait for a scheduled appointment.

The label change does not mean GLP-1 drugs are risk-free. They have well-documented side effects including gastrointestinal effects, injection site reactions, and for some patients, hair loss. The specific concern about suicidality, however, has been investigated extensively and not confirmed.

For Clinicians: Practical Takeaways

The FDA’s label change request does not eliminate the clinical rationale for psychiatric monitoring in GLP-1 users. The population prescribed these drugs has elevated baseline psychiatric risk, and the co-prescription signal (antidepressants, benzodiazepines) warrants awareness even if it likely reflects underlying vulnerability rather than a drug effect.

Discuss realistic treatment expectations before initiating GLP-1 therapy. The umbrella review found that unrealistic expectations and disappointment with weight loss results were associated with elevated suicidal risk signals. Setting evidence-based expectations, specifically that 10 to 15% weight loss is typical and results vary, is now both good clinical practice and supported by the safety literature.

The review’s psychiatric adverse event finding is broader than suicidality. No increased risk of anxiety, depression, irritability, or psychosis was found across 91 trials. This is useful context for reassuring patients who ask about neuropsychiatric effects broadly.

For patients with a history of suicidality or active psychiatric illness who are candidates for GLP-1 therapy, consider co-management with their mental health provider, not because of drug risk but because of the baseline complexity.

For related HED coverage of GLP-1 medications and their evolving indications, see our posts on GLP-1 medications and PCOS fertility research in 2026, the approval of Wegovy HD (semaglutide 7.2 mg) and the STEP UP trial data, and the FDA’s post-marketing study requirements for Foundayo (orforglipron).

If you or someone you know is struggling with mental health right now, please reach out to the 988 Suicide and Crisis Lifeline by calling or texting 988, available 24 hours a day, 7 days a week in the U.S.

Sources

FDA Drug Safety Communication (Jan 2026): Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking Certain Type 2 Diabetes and Obesity Medicines. January 13, 2026. fda.gov.

Pharmacy Times coverage: FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Removal of Warning Labels. pharmacytimes.com. 2026.

EMA review conclusion: European Medicines Agency. Assessment report on GLP-1 receptor agonists and risk of suicidal behavior and ideation. April 2024.

McIntyre et al. FAERS analysis: McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. Association between GLP-1 RAs and suicidality using Bradford Hill criteria. Expert Opin Drug Saf. 2024;23(1):47-55. doi:10.1080/14740338.2023.2295397

Nature Medicine cohort: Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. doi:10.1038/s41591-023-02750-1

Bushi et al. systematic review: Bushi G et al. Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis. Diabetes Metab Res Rev. 2025. doi:10.1002/dmrr.70037

Umbrella review: Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence. Healthcare (MDPI). 2025;13(22):2958. doi:10.3390/healthcare13222958

ScienceDirect systematic review: The effect of GLP-1 receptor agonists on measures of suicidality: A systematic review. ScienceDirect. 2025. doi:10.1016/j.jad.2025.01.007

Lancet eClinical case-time-control: Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102983

Mendelian randomization: Nguyen et al. Causal assessment of GLP-1 RA effects and suicide attempts via Mendelian randomization. 2024.

FDA Sentinel System: FDA’s Sentinel Initiative. fda.gov/safety/fdas-sentinel-initiative.

Bradford Hill criteria reference: Bradford Hill Criteria. PMC4589481.

GLP-1 receptor agonist overview: GLP-1 Receptor Agonists. StatPearls. NCBI.

SGLT2 inhibitor overview: SGLT2 Inhibitors. StatPearls. NCBI.

Crisis resources: 988 Suicide and Crisis Lifeline. 988lifeline.org. Call or text 988, available 24/7.

Disclaimer: Health Evidence Digest provides general information about drug safety research for educational purposes. This content is not a substitute for professional medical advice. If you are experiencing thoughts of self-harm or suicide, contact 988 or seek emergency care immediately. Do not stop prescribed medications without consulting your healthcare provider.

April 5, 2026

365 Injections a Year, or 52. Awiqli Is the First Once-Weekly Basal Insulin and the Science Behind It Is More Interesting Than the Dosing Schedule.

📌 The essentials On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae, Novo Nordisk), the first and only once-weekly basal insulin in history, for adults with type 2 diabetes. 52 injections per year instead of 365. The clinical basis: four randomized, treat-to-target ONWARDS Phase 3 trials enrolling approximately 2,900 adults with T2D. Three of the four trials showed statistically superior HbA1c reduction with icodec versus daily basal insulin. The fourth met non-inferiority. A meta-analysis across five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003). The mechanism: insulin icodec binds reversibly to albumin via fatty acid side chains, creating a circulating reservoir that releases active insulin continuously over approximately 8 days (half-life approximately 196 hours). Why the T1D indication is absent: an earlier FDA Complete Response Letter cited the higher hypoglycemia rate in ONWARDS 6 (the type 1 trial). The March 2026 approval covers type 2 diabetes only. Critical clinical consideration: icodec’s 196-hour half-life means dose adjustments take 3 to 4 weeks to reach new steady state. Titrate conservatively, no more frequently than every 1 to 2 weeks.

Basal insulin has been a cornerstone of type 2 diabetes management for decades. It works by providing a slow, steady background level of insulin that covers overnight glucose production by the liver and keeps blood sugar from rising between meals. For millions of people with type 2 diabetes who cannot achieve adequate glycemic control with oral medications alone, basal insulin is not optional. It is what keeps them safe.

But daily injections are a burden. Not a small one. A patient starting daily basal insulin at age 60 faces 365 injections per year for the rest of their life. Studies consistently show that fear of injection, injection fatigue, and the daily management burden contribute to insulin omission, dose skipping, and delayed treatment initiation, all of which translate into worse glycemic control and worse outcomes.

On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin in history, 52 injections a year instead of 365. The clinical data behind it spans five randomized trials and approximately 4,000 patients. It shows not just non-inferiority to daily basal insulin, but in several studies, superior HbA1c reduction. Understanding how that is possible, and what the trade-offs are, requires going inside the chemistry.

How Awiqli Actually Works: The Albumin-Binding Depot Mechanism

Existing basal insulins, glargine (Lantus, Toujeo, Basaglar) and degludec (Tresiba), achieve their extended duration through different mechanisms. Glargine precipitates at physiological pH, forming microcrystals that dissolve slowly. Degludec forms multi-hexameric chains that dissociate gradually from the injection site. Both produce half-lives of 12 to 25 hours, sufficient for once-daily dosing.

Insulin icodec takes a fundamentally different approach. The molecule is engineered with two fatty acid side chains that allow it to bind reversibly to albumin, the most abundant protein in blood plasma. When injected, icodec does not just sit at the injection site waiting to dissolve. It enters the bloodstream and binds to circulating albumin, which acts as a reservoir. Only a small fraction of icodec is free and active at any given time; the rest is temporarily sequestered in the albumin-bound depot. As free icodec is cleared by the body, more is released from albumin to replace it.

The result is a half-life of approximately 196 hours, about 8 days. This is long enough that a single injection provides stable, continuous insulin coverage for an entire week, with a flat pharmacodynamic profile that avoids the peak-and-trough pattern that can contribute to hypoglycemia with shorter-acting insulins.

Why the long half-life creates a specific clinical consideration The same pharmacokinetic property that enables once-weekly dosing also means that any dose adjustment takes longer to reach a new steady state. With daily insulin, a dose increase or decrease produces a measurable effect within 1 to 2 days. With icodec’s 196-hour half-life, it takes approximately 3 to 4 weeks to reach a new steady state after a dose change. This has a practical implication for titration: icodec should be titrated conservatively, with dose adjustments made no more frequently than every 1 to 2 weeks based on fasting blood glucose. Aggressive titration, adjusting every few days as some patients do with daily insulins, risks overshoot and delayed hypoglycemia. The prescribing information provides specific titration guidance that clinicians should review carefully. Similarly, if a patient is transitioning off icodec to another insulin, the insulin effect persists for several days after the last dose. Overlap with a new insulin must be carefully managed to avoid hypoglycemia during the transition period.

Why This Is a Resubmission and Why Type 1 Diabetes Is Not on the Label

The March 2026 approval is not the first time Awiqli went through FDA review. In July 2024, the FDA issued a Complete Response Letter citing two issues: concerns about the manufacturing process, and concerns about the safety of insulin icodec specifically in patients with type 1 diabetes.

The type 1 concern is worth understanding. ONWARDS 6, the Phase 3 trial evaluating insulin icodec in T1D, showed that icodec was non-inferior to degludec for HbA1c reduction. But in T1D patients, the rate of clinically significant or severe hypoglycemia was meaningfully higher in the icodec arm than in the degludec arm. The FDA’s advisory committee voted against approval for T1D, and the agency’s concerns were reflected in the CRL.

Novo Nordisk’s response was pragmatic: rather than try to address the T1D concerns in the resubmission, which would have required additional clinical data and further delayed approval, the company resubmitted in September 2025 for the T2D indication only, where the efficacy and safety data were consistently robust. That resubmission was approved in March 2026.

Novo Nordisk has stated that it remains committed to exploring icodec for type 1 diabetes and plans to conduct a new clinical trial in this population. The T1D indication is not closed; it is deferred. For now, Awiqli is approved for adults with type 2 diabetes only.

The ONWARDS Trials: What the Clinical Evidence Shows

The FDA approval is based on four trials from the ONWARDS Phase 3a clinical program, all randomized, active-controlled, and treat-to-target in design. “Treat-to-target” means that insulin doses in both arms were titrated to achieve the same blood sugar goals, a rigorous design that tests whether the drugs perform equivalently under optimized conditions.

Trial	Population	Comparator	HbA1c reduction (icodec)	HbA1c reduction (comparator)
ONWARDS 1 (78 wk, n=984)	Insulin-naive T2D on non-insulin agents	Glargine U100 (once daily)	−1.55%	−1.35%*
ONWARDS 2 (26 wk, n=526)	T2D switching from daily basal insulin	Degludec (once daily)	−0.93%	−0.71%†
ONWARDS 3 (26 wk, n=588)	Insulin-naive T2D on non-insulin agents	Degludec (once daily)	−1.57%	−1.36%†
ONWARDS 4 (26 wk, n=582)	T2D on basal-bolus regimen	Glargine U100 (once daily)	−1.16%	−1.18% (NI met)

* Superior (p less than 0.001) vs. glargine U100. † Superior (p less than 0.003 to p less than 0.0007) vs. degludec. NI = non-inferiority. Source: Published ONWARDS trials in NEJM, Lancet, JAMA, Lancet Diabetes Endocrinology.

Three of the four trials showed statistically superior HbA1c reduction with icodec compared to daily basal insulin. The fourth (ONWARDS 4, in patients already on basal-bolus regimens) met the pre-specified non-inferiority margin. A meta-analysis across all five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003) and an odds ratio of 1.51 (95% CI 1.14 to 1.99) for achieving HbA1c below 7% with icodec versus comparators.

ONWARDS 1 also demonstrated a secondary endpoint of superior Time in Range (blood glucose 70 to 180 mg/dL) with icodec compared to glargine U100, a clinically meaningful finding given the growing emphasis on TIR as an outcome measure alongside HbA1c. Additionally, in ONWARDS 1 and 3, a higher proportion of insulin-naive patients achieved an HbA1c target below 7% without clinically significant or severe hypoglycemia with icodec versus comparators, suggesting that the once-weekly drug can deliver better glycemic control without proportionally increasing hypoglycemia burden in this population.

Dr. Julio Rosenstock, MD, Clinical Professor at UT Southwestern Medical Center and Principal Investigator of the ONWARDS trial program, characterized the approval at the time of the FDA decision as underscoring the need for new alternative insulin options that may help patients work with their healthcare providers to determine what treatment works best for them.

The Hypoglycemia Picture: Nuanced, Not Alarming

Hypoglycemia is the most important safety consideration in any insulin therapy, and the icodec data requires careful interpretation rather than a headline summary.

In insulin-naive patients (ONWARDS 1 and 3), the picture is favorable: despite achieving better HbA1c control, icodec did not generate significantly more hypoglycemia than comparators, and more patients reached target HbA1c without experiencing level 2 or level 3 hypoglycemia.

The nuance comes in the switching studies (ONWARDS 2 and 3 for patients already on insulin). Here, numerically higher rates of clinically significant (level 2) or severe (level 3) hypoglycemia were observed with icodec compared to degludec. In ONWARDS 3, rates were 0.31 versus 0.15 events per patient-year. This difference reflects a specific pharmacokinetic challenge: when patients switch from daily to weekly insulin, there is an initial period during which the full icodec depot is being established. The prescribing information recommends initiating icodec at 20% higher than the previous total daily dose for patients switching from daily basal insulin, specifically to manage this titration period.

The clinical alert on hypoglycemia in T2D Patients treated with Awiqli tended to have a greater incidence of hypoglycemia than daily comparators in some study arms, while in insulin-naive patients the rates were comparable or favorable. The key implication is that icodec requires more careful patient selection and titration guidance when used as a switch therapy versus a treatment initiation therapy. In T2D specifically, the clinical concern about hypoglycemia is lower than in T1D: T2D patients retain some endogenous insulin secretion and have counterregulatory responses that protect against severe hypoglycemia. The T1D population, where hypoglycemia was more concerning and drove the CRL, is not included in the current U.S. approval. For T2D, the FDA and the ONWARDS investigators judged the benefit-risk profile favorable.

Practical Use: Dosing, Switching, and Missed Doses

The U-700 concentration: what this means practically

Awiqli is a U-700 formulation, 700 units per mL, compared to the U-100 (100 units per mL) that most daily basal insulins use. This higher concentration is what allows a full week’s worth of insulin to be administered in a single manageable injection volume. It means that icodec is not substitutable unit-for-unit with daily insulins: a week’s dose of icodec is roughly equivalent to 7 days of the total daily dose, not a single daily dose. Careful dose calculation is required at initiation and when switching.

Starting doses and switching guidance

Patient situation	Starting approach
Insulin-naive	Start at 70 units once weekly. Titrate based on fasting blood glucose, adjusting no more than every 2 weeks.
Switching from daily basal insulin	Start at 20% higher than previous total daily basal dose, given once weekly. This accounts for the accumulation phase.
Adding to GLP-1 or oral agents	Start at 70 units weekly (same as insulin-naive). Be alert to enhanced glucose-lowering from the combination.
Patients on basal-bolus regimens	Switch based on individual assessment; the ONWARDS 4 data supports the transition in this population.

Missed dose flexibility: a genuine practical advantage

One underappreciated benefit of icodec’s long half-life is missed-dose forgiveness. Because the drug accumulates in the albumin depot and releases continuously, a missed or shifted dose is less clinically consequential than with daily insulin. The prescribing information states that if a dose is missed, it can be administered up to 3 days (72 hours) before or after the scheduled day. After administration, resume the original once-weekly schedule. This flexibility directly addresses one of the practical frustrations of daily insulin, the anxiety around a forgotten or delayed dose.

Administration

Awiqli is administered subcutaneously once weekly on the same day each week, using the Novo Nordisk FlexTouch prefilled pen. It is available in three pen sizes: 700 units per 1 mL, 1050 units per 1.5 mL, and 2100 units per 3 mL. It must not be administered intravenously, intramuscularly, or via insulin pump, and must not be mixed with other insulin products.

Safety: What the Prescribing Information Covers

The safety profile of Awiqli is broadly consistent with the basal insulin class, with the nuances around hypoglycemia and titration already discussed above.

Common adverse reactions: hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy (skin thickening or pitting at injection sites), pruritus, rash, peripheral edema, weight gain.

Serious risks:

Severe hypoglycemia
Serious hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and swelling of face and lips
Hypokalemia (low potassium, which may affect heart rhythm)

Thiazolidinediones (TZDs): Use with pioglitazone or rosiglitazone increases the risk of fluid retention and potential heart failure exacerbation. Monitor for signs of heart failure when co-prescribing.

Acute illness and fasting: During illness or significant changes in eating, blood glucose monitoring frequency should increase and dose adjustments may be needed. The long half-life means that missed or delayed doses are tolerated, but significant metabolic stress (surgery, serious illness) requires closer glucose monitoring.

Not indicated for: ketoacidosis treatment, diabetic ketoacidosis, use via intravenous or intramuscular routes, or use with insulin infusion pumps.

Why Injection Frequency Matters More Than It Might Seem

The clinical significance of moving from daily to weekly injections goes beyond convenience. The diabetes literature on insulin adherence is consistent: injection burden is one of the leading modifiable barriers to insulin initiation and continuation. “Psychological insulin resistance,” the phenomenon in which patients delay or avoid starting insulin despite clinical need, is documented in 20 to 30% of people with T2D who are recommended insulin.

Insulin omission is also common among those already on therapy: studies estimate that 20 to 50% of patients on daily basal insulin skip doses at least occasionally, with higher rates among those with greater injection frequency or complex regimens. Each omitted dose represents a period of inadequate glycemic coverage. Sustained omission accelerates the development of diabetes complications.

Once-weekly dosing does not eliminate these barriers, but it substantially reduces the number of opportunities for omission and lowers the daily psychological overhead of managing insulin therapy. Whether this translates into measurably better real-world outcomes beyond what the controlled trials demonstrated will only be known from post-marketing evidence. But the mechanistic argument is sound.

Availability and Global Status

Novo Nordisk has indicated Awiqli will be available at U.S. pharmacies in the second half of 2026. The drug has already been approved in the European Union, Canada, Australia, Japan, Switzerland, and more than a dozen other countries, in many of those markets for both type 1 and type 2 diabetes. The U.S. approval is limited to type 2 diabetes.

Pricing and formulary coverage have not been announced for the U.S. market at time of writing. Patients and clinicians should check with their insurance provider and Novo Nordisk’s patient support resources as the launch approaches. For patients on insulin experiencing cost barriers, the Novo Nordisk patient assistance program and the NeedyMeds database are useful starting points.

For related HED coverage on diabetes treatment advances and access, see our posts on the FDA approval of the first generic dapagliflozin tablets and the approval of Foundayo (orforglipron), the first oral GLP-1 pill for weight management without food or water restrictions.

Sources

FDA approval and Novo Nordisk press release: FDA approves Novo Nordisk’s Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with T2D. March 26, 2026. prnewswire.com.

HCPLive coverage: FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. hcplive.com. March 2026.

Patient Care Online coverage: FDA Approves Once-Weekly Basal Insulin for Adults With Type 2 Diabetes. patientcareonline.com. March 2026.

Consultant360: FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin. consultant360.com. March 2026.

ONWARDS 1 (NEJM): Rosenstock J et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. NEJM. 2023;389(16):1533. doi:10.1056/NEJMoa2310221

ONWARDS 2 (Lancet Diabetes Endocrinol): Philis-Tsimikas A et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated T2D (ONWARDS 2). Lancet Diabetes Endocrinol. 2023.

ONWARDS 3 (JAMA): Lingvay I et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive T2D: ONWARDS 3. JAMA. 2023;330(3):228-237.

ONWARDS 4 (Lancet): Mathieu C et al. Switching to once-weekly icodec vs once-daily glargine U100 in basal-bolus insulin-treated T2D (ONWARDS 4). Lancet. 2023.

ONWARDS 1 trial registration: NCT04508660. ClinicalTrials.gov.

ONWARDS 2 trial registration: NCT04771052. ClinicalTrials.gov.